UBS Group’s Verve Therapeutics VERV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1,870,522
| Closed | -$21M | – | 10970 |
|
|
2025
Q2 | $21M | Buy |
1,870,522
+1,738,749
| +1,320% | +$9.91M | ﹤0.01% | 2310 |
|
|
2025
Q1 | $602K | Sell |
131,773
-8,016
| -6% | -$53.7K | ﹤0.01% | 5708 |
|
|
2024
Q4 | $788K | Sell |
139,789
-24,338
| -15% | -$137K | ﹤0.01% | 5491 |
|
|
2024
Q3 | $794K | Buy |
164,127
+57,425
| +54% | +$334K | ﹤0.01% | 4856 |
|
|
2024
Q2 | $521K | Sell |
106,702
-185,282
| -63% | -$1.16M | ﹤0.01% | 4969 |
|
|
2024
Q1 | $3.88M | Buy |
291,984
+88,633
| +44% | +$1.18M | ﹤0.01% | 3244 |
|
|
2023
Q4 | $2.83M | Buy |
203,351
+120,088
| +144% | +$1.49M | ﹤0.01% | 3439 |
|
|
2023
Q3 | $1.1M | Sell |
83,263
-4,811
| -5% | -$77.5K | ﹤0.01% | 3978 |
|
|
2023
Q2 | $1.65M | Sell |
88,074
-2,761
| -3% | -$46K | ﹤0.01% | 3714 |
|
|
2023
Q1 | $1.31M | Sell |
90,835
-152,939
| -63% | -$2.99M | ﹤0.01% | 3860 |
|
|
2022
Q4 | $4.72M | Buy |
243,774
+210,071
| +623% | +$5.57M | ﹤0.01% | 2555 |
|
|
2022
Q3 | $1.16M | Buy |
33,703
+33,553
| +22,369% | +$1.07M | ﹤0.01% | 3636 |
|
|
2022
Q2 | $2K | Sell |
150
-106,101
| -100% | -$1.64M | ﹤0.01% | 9627 |
|
|
2022
Q1 | $2.42M | Buy |
106,251
+81,921
| +337% | +$2.34M | ﹤0.01% | 3249 |
|
|
2021
Q4 | $897K | Buy |
24,330
+21,030
| +637% | +$883K | ﹤0.01% | 4486 |
|
|
2021
Q3 | $155K | Buy |
3,300
+1,769
| +116% | +$104K | ﹤0.01% | 5518 |
|
|
2021
Q2 | $92K | Buy |
+1,531
| New | +$63.5K | ﹤0.01% | 5956 |
|
Other funds holding VERV
GCM
BIG
IA
